Gene: KCNH5

27133
EAG2|H-EAG2|Kv10.2|hEAG2
potassium voltage-gated channel subfamily H member 5
protein-coding
14q23.2
Ensembl:ENSG00000140015 MIM:605716 Vega:OTTHUMG00000029041 UniprotKB:Q8NCM2
NG_034062.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.741e-1 (AD)  4.914e-2 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KCNH10.919
SCN8A0.903
GRIN2A0.895
MTUS20.893
PCDHAC20.884
FAM78B0.882
GRM50.877
NBEA0.874
HECW10.873
FMN10.871

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
HEY2-0.636
ROM1-0.617
RAB13-0.596
COPZ2-0.592
YES1-0.586
STON2-0.582
AGTRAP-0.574
CHST14-0.574
ALDH3B1-0.571
TRIP6-0.57

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of KCNH5 mRNA26690555
D000082AcetaminophenAcetaminophen affects the expression of KCNH5 mRNA17562736
D000111Acetylcysteine[indole-3-carbinol co-treated with Diethylnitrosamine co-treated with Acetylcysteine] results in decreased expression of KCNH5 mRNA22129741
D019386AlendronateAlendronate affects the expression of KCNH5 mRNA16079270
D000643Ammonium ChlorideAmmonium Chloride affects the expression of KCNH5 mRNA16483693
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of KCNH5 mRNA22316170
D001564Benzo(a)pyreneBenzo(a)pyrene promotes the reaction [AHR protein binds to KCNH5 promoter]19654925
C006780bisphenol Abisphenol A results in decreased expression of KCNH5 mRNA25181051
C055494caffeic acid phenethyl ester[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of KCNH5 mRNA20360939
D002994ClofibrateClofibrate results in increased expression of KCNH5 mRNA22300585
D004041Dietary FatsDietary Fats results in increased expression of KCNH5 mRNA21852083
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of KCNH5 mRNA20360939
D004052Diethylnitrosamine[indole-3-carbinol co-treated with Diethylnitrosamine co-treated with Acetylcysteine] results in decreased expression of KCNH5 mRNA22129741
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of KCNH5 mRNA16079270
C016517indole-3-carbinol[indole-3-carbinol co-treated with Diethylnitrosamine co-treated with Acetylcysteine] results in decreased expression of KCNH5 mRNA22129741
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of KCNH5 mRNA"20188158
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of KCNH5 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of KCNH5 mRNA26272509
D059808PolyphenolsPolyphenols results in decreased expression of KCNH5 mRNA16293270
D011192Potassium DichromatePotassium Dichromate results in decreased expression of KCNH5 mRNA23608068
D011441PropylthiouracilPropylthiouracil results in decreased expression of KCNH5 mRNA24780913
C502851quinocetonequinocetone results in increased expression of KCNH5 mRNA27046791
D020849Raloxifene HydrochlorideRaloxifene Hydrochloride affects the expression of KCNH5 mRNA16079270
D014212TretinoinTretinoin results in decreased expression of KCNH5 mRNA21934132
C012589trichostatin Atrichostatin A results in decreased expression of KCNH5 mRNA24935251
C012589trichostatin Atrichostatin A results in increased expression of KCNH5 mRNA24935251
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of KCNH5 mRNA24383497|2627250
D014635Valproic AcidValproic Acid results in increased expression of KCNH5 mRNA28001369
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of KCNH5 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000155phosphorelay sensor kinase activity-IEA-  
GO:0005249voltage-gated potassium channel activity-IBA21873635  
GO:0005516calmodulin binding-IEA-  
GO:0044325ion channel binding-IEA-  
GO:0046982protein heterodimerization activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000160phosphorelay signal transduction system-IEA-  
GO:0010389regulation of G2/M transition of mitotic cell cycle-IDA22855790  
GO:0023014signal transduction by protein phosphorylation-IEA-  
GO:0034765regulation of ion transmembrane transport-IEA-  
GO:0042391regulation of membrane potential-IBA21873635  
GO:0071805potassium ion transmembrane transport-IBA21873635  
GO:0071805potassium ion transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005622intracellular-IDA22855790  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0009986cell surface-IDA22855790  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-112316Neuronal SystemTAS
R-HSA-1296071Potassium ChannelsTAS
R-HSA-1296072Voltage gated Potassium channelsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
18349282DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. (2008 Mar)Feng QCancer Epidemiol Biomarkers Prev